A new class of ophthalmic drug continues to show promise for treating patients with diabetic macular edema (DME).
Lynda Charters
Advertisement
Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.
Articles by Lynda Charters
Advertisement
Advertisement
Advertisement